What to do about Allergies
Content restricted. Requires subscription
In brief: Antipsychotic choice in early-onset schizophrenia
A study of antipsychotic medications in the treatment of young patients found more evidence that first- and second-generation drugs are not particularly effective.
Content restricted. Requires subscription
Mild cognitive impairment
Mild cognitive impairment is considered to be the state between normal mental function and dementia. Researchers are seeking a way to diagnose the condition sooner, so that medication can be used to treat or at least manage it, to keep it from worsening.
Content restricted. Requires subscription
The psychological impact of infertility and its treatment
Most instances of infertility have a physiological cause, but the emotional and mental toll is significant, and fertility treatments can add to the stress.
Content restricted. Requires subscription
Revisiting the CATIE schizophrenia study
A long-term trial of schizophrenia drugs has found that newer medications are not any more effective than a first-generation drug, but questions have been raised about the parameters of the study.
Content restricted. Requires subscription
In Brief: Unmet mental health needs
The World Health Organization found that many people worldwide are not receiving needed mental health care and services.
Content restricted. Requires subscription
In Brief: Research suggests why stress may add pounds
In experiments on mice, suppressing a chemical linked to stress and appetite prevented the formation of abdominal fat cells, which could lead to new possibilities for weight loss drugs.
Content restricted. Requires subscription
Vioxx Articles Ghostwritten, Journal Says
Reports in a medical journal claim that Merck & Co. paid outside scientists to be listed as authors of articles written by ghostwriters. The articles included research on Vioxx. This drug was withdrawn from the market in 2004 because of heart and stroke risks. The new reports also say that Merck tried to minimize the death risk in two studies related to Vioxx and Alzheimer’s disease. But Merck told the Associated Press that the new reports were false and misleading. It said the listed authors were closely involved in the research. Merck said the Alzheimer’s articles were accurate. The company also said the new reports were biased because their authors had consulted for people who sued Merck over Vioxx. The reports were published April 16 in the Journal of the American Medical Association.
Content restricted. Requires subscription
Neurofeedback for attention deficit hyperactivity disorder
Mixed results in tests of medications for the treatment of ADHD have led to interest in neurofeedback as a possible alternative, but research into its effectiveness has not been conclusive so far.
Content restricted. Requires subscription
Dental Health for Adults: A guide to protecting your teeth and gums
Content restricted. Requires subscription